cd4 hiv dr a singh

Information about cd4 hiv dr a singh

Published on April 17, 2008

Author: Peppar

Source: authorstream.com

Content

CD4 for monitoring HIV Progression:  CD4 for monitoring HIV Progression 31st Annual National Conference of Indian Association of Preventive & Social Medicine, 27th – 29th Feb 2004 PGIMER, Chandigarh Dr. Arvinder Singh BD Biosciences BD Activities:  Brazil -COOPEX -MOH -BDB BD Activities Slide3:  HIV/AIDS What is CD4/CD8 Flow Cytometry Clinical Applications:  Flow Cytometry Clinical Applications HIV immunophenotyping (CD4 absolute counts) Cytokine analysis Leukemia and lymphoma diagnosis - minimum residual disease detection Cell cycle and DNA ploidy analysis Stem Cell Analysis HLA – B 27 Typing Residual white blood cell detection Reticulocyte enumeration Flow crossmatching (organ transplantation) What Is Flow Cytometry?:  What Is Flow Cytometry? A technology that simultaneously measures multiple characteristics of single cells at a rapid rate Lysed Whole Blood:  Lysed Whole Blood Neutrophils Monocytes Lymphocytes Side Scatter Forward Light Scatter Two-Color Cell Analysis:  Two-Color Cell Analysis CD8 PE CD4 FITC 10 0 10 0 10 1 10 2 10 3 10 4 10 1 10 2 10 3 10 4 Slide14:  Four color analysis CD4 Cy5 CD8 PE CD45 PerCP CD3 FITC CD8 PE CD3 FITC SSC Height CD4 Cy5 Slide15:  42 Million People Living with AIDS India – Current Situation HIV:  India – Current Situation HIV HIV prevalence rate is 0.7% India has had a sharp increase in the estimated number of HIV infections, from a few thousand in the early 1990s to a working estimate of about 3.8 million children and adults living with HIV/AIDS in 2001 Estimates range from 8 - 15 million HIV infected adults and children living with HIV in 2010 Given India's large population, a mere 0.1 percent increase in the prevalence rate would increase the number of adults living with HIV/AIDS by over half a million people India – Current Situation HIV:  India – Current Situation HIV About 90% of the total reported AIDS cases occur in the sexually active and economically productive 15 to 44 age group Men account for 79% of HIV infections in India The predominant mode of HIV transmission is through heterosexual contact In 2001, the HIV infection rate went above one per cent in six states Maharashtra, Tamil Nadu and Manipur - account for 75% of estimated HIV cases the burden of AIDS cases is beginning to be felt in states affected early - Mumbai and Manipur have recorded 20 to 49 per cent bed occupancy by HIV positive people in certain hospitals HIV/AIDS Pandemic:  HIV/AIDS Pandemic Disease Management Vaccines, Drugs, Education Antiretroviral Therapy (ART) Controls disease progression Increasing drug resistance patterns Expensive (Big Pharma – western countries) Trend to affordable (generic) drugs in developing world   CD4 T-Lymphocyte Count   Flow cytometry is gold standard Alternate technologies – currently inadequate FacsCount is considered system of choice CD4 count is the single most important objective criteria to guide clinical decision-making on when to use ART HIV Testing paradigm:  HIV Testing paradigm Screen Confirm* CD4 Viral load 15-20M 1-2M 4-6M 5-8M Est. annual tests *(includes genotyping) PCR Viral load:  PCR Viral load It is a technique that imitates a cell’s ability to replicate DNA by generating multiple copies of specific sequences of DNA through amplification. In clinical diagnostics, a specimen of genetic material can be repeatedly copied by PCR to provide sufficient material to detect the presence or absence of a virus as well as to quantitate its levels in the blood. It’s used for: The development of new drugs To establish a patient’s disease status and the likelihood of disease progression To determine when to start treatment To help the physician decide which drugs to use in a treatment regimen To assess whether a treatment regimen is working CD4 and viral load:  CD4 and viral load HIV/AIDS Pandemic:  HIV/AIDS Pandemic Situational Analysis Unmet Needs   Affordable drugs/ART   Affordable CD4 Flow Cytometry:  Flow Cytometry GOLD STANDARD FOR CD4/CD8 Monitoring in HIV/AIDS Patients Conceptually established by BD Worldwide FACSCount - Complete System IVD approved ( US FDA ):  FACSCount - Complete System IVD approved ( US FDA ) FACSCount - Complete System:  Premeasured Reagents FACSCount - Complete System FACSCount - Complete System:  FACSCount Reagents and Controls FACSCount Workstation FACSCount - Complete System FACSCount:  FACSCount Measuring Absolute CD4, CD8 and CD3 Counts In Three Easy Steps FACSCount - Clinical Need:  Safety Minimal Sample Preparation Fixed Samples Absolute Counts Limited Handling of Biohazardous Samples FACSCount - Clinical Need FACSCount - Clinical Need:  Easy to use Absolute Counts Unit Dose Reagents Minimal Hands-On Time No Formal Training Required FACSCount - Clinical Need FACSCounts in India:  35 Placements 23 Instruments through NACO 12 Instruments in Private Path Laboratories FACSCounts in India Reference Range of Lymphocytes Subsets In Healthy Individuals (India):  Reference Range of Lymphocytes Subsets In Healthy Individuals (India) MALES CD3+ 617 – 2485 CD19+ 125 – 701 CD4+ 337 – 1090 CD8+ 174 – 1240 Ratio 0.61 – 2.68 HIV Patients-Low CD4 FEMALES CD3+ 898 – 2786 CD19+ 119 – 721 CD4+ 424 – 1050 CD8+ 255 – 1353 Ratio 0.95 – 2.40 FACSCount - Analysis:  A hard copy results The control Patient sample FACSCount - Analysis HIV Monitoring:  HIV Monitoring Appropriate Technology Flow Cytometry Capacity Building Training, Support, Service BD provides a gold standard system of reliable products and support services for CD4+ T-cell testing at affordable pricing. Reliable Laboratory Systems GMP/GLP (IVDP)/GCP Performance of Competitive Tests:  Performance of Competitive Tests Pharmas taking action:  Pharmas taking action Abbott Laboratories Bristol-Meyers Squibb GlaxoSmithKline Hoffmann La-Roche Ltd Boehringer Ingelheim Merck & Co., Inc Pfizer Cipla Ranbaxy Matrix Slide36:  General concensus is that flow cytometry based CD4 count is the most accepted technique to HIV monitoring Quantitative – more cells counted, more reliable result Specific – mAb, identify CD4 T-lymphocytes most precisely QA/QC – internal and external - necessary for accreditation Throughput – manual operation is acceptable as technician costs are not significant and does not limit test demand Existing flow cytometry systems (FACSCalibur or similar) are adequate/accepted for Central Reference facilities – usually at the sites of principal government services Perform broad clinical testing plus Research studies associated with international partners Affordable lower cost platform required at Provincial and Local clinic sites – dedicated clinical test platform Capability to perform CD4 count ( - ideal with broader test menu ) Current FACSCount system should be viewed as maximal technology complexity – sample preparation potential issue – reagent cost limitation Challenge from Partec / Guava like technology or alternative assays Application Comparison:  Application Comparison Slide38:  Affordable Testing for HIV/AIDS in the Developing World February 5, 2004 On January 14, 2004, the William J. Clinton Presidential Foundation announced that BD, through BD Biosciences, had entered into an agreement with the Foundation to provide affordable CD4 testing, both reagents and instruments, to the poorest and most severely HIV/AIDS afflicted areas in the developing world. The CD4 immunocytometry test has been used to establish decision points for antiretroviral (ARV) therapy, to monitor efficacy of various treatments, as a prognostic indicator, and as one criterion for initiating prophylaxis for opportunistic infections. The viral load test helps measure how effective ARV therapies are in suppressing the virus and can alert clinicians about the need to adjust dosages or change regimens. BD Biosciences Accomplishing our Mission – HIV/AIDS:  BD Biosciences Accomplishing our Mission – HIV/AIDS BD Biosciences is Helping With the Global AIDS Crisis by: Supporting the Brazilian AIDS prevention program Example program for reducing mortality and new infections in the developing world Our flow instruments and reagents are used as the gold standard to monitor disease progression in HIV-infected individuals Collaborating with the International AIDS Vaccine Initiative (IAVI) Speed the development and distribution of preventive AIDS vaccines Our flow instruments and reagents are used to detect immune response to the vaccine HIV/AIDS :  HIV/AIDS 2010 80+ million PLWHA India (15+ million) China (15+ million) Negative growth rates in most of Africa due to AIDS mortality WW economic impact   2002 Brazil Achieves 50% reduction in AIDS deaths over last 10 years Accessible drugs and health care $500,000 million savings on AIDS impact PANDEMIC

Related presentations


Other presentations created by Peppar

Financial Statement Analysis
10. 04. 2008
0 views

Financial Statement Analysis

Dr PH Presentation
07. 08. 2007
0 views

Dr PH Presentation

Burj Al Arab
22. 04. 2008
0 views

Burj Al Arab

Philip Scott
17. 04. 2008
0 views

Philip Scott

RMIT 25July01 Pres
14. 04. 2008
0 views

RMIT 25July01 Pres

060125
13. 04. 2008
0 views

060125

Blomqvist
09. 04. 2008
0 views

Blomqvist

Rocks and Weathering
20. 09. 2007
0 views

Rocks and Weathering

Your First RSS Feed
29. 09. 2007
0 views

Your First RSS Feed

Switzerland
15. 10. 2007
0 views

Switzerland

t infantil y legislacion
22. 10. 2007
0 views

t infantil y legislacion

14501
07. 10. 2007
0 views

14501

MAHA Talk
29. 10. 2007
0 views

MAHA Talk

Stylish Sentences
02. 11. 2007
0 views

Stylish Sentences

15 GardnerHarris
19. 11. 2007
0 views

15 GardnerHarris

cryptorchidism
19. 11. 2007
0 views

cryptorchidism

geometry and art P2
22. 11. 2007
0 views

geometry and art P2

Green Bldgs and WQ
31. 12. 2007
0 views

Green Bldgs and WQ

paper2
03. 01. 2008
0 views

paper2

Earthquakes Chap 5
20. 09. 2007
0 views

Earthquakes Chap 5

Ch08
20. 09. 2007
0 views

Ch08

El Paso Electric lowres pics
07. 08. 2007
0 views

El Paso Electric lowres pics

AG presentation Infrastructure
07. 08. 2007
0 views

AG presentation Infrastructure

GCRA Presentation 2005 1
07. 08. 2007
0 views

GCRA Presentation 2005 1

Asian Alphabet Book 04 17 06
07. 08. 2007
0 views

Asian Alphabet Book 04 17 06

pres maldives
07. 08. 2007
0 views

pres maldives

Tsunami Effects
07. 08. 2007
0 views

Tsunami Effects

Maldives
07. 08. 2007
0 views

Maldives

Global gs pp 0207
22. 10. 2007
0 views

Global gs pp 0207

feist ch14McCrae
06. 08. 2007
0 views

feist ch14McCrae

measurement and geometry
07. 08. 2007
0 views

measurement and geometry

arguments
15. 11. 2007
0 views

arguments

Tidal Energy Overview7
07. 08. 2007
0 views

Tidal Energy Overview7

camoa presse spip 01
07. 08. 2007
0 views

camoa presse spip 01

PE Rocks Igneous
20. 09. 2007
0 views

PE Rocks Igneous

ROCKS and how to identify them
20. 09. 2007
0 views

ROCKS and how to identify them

RIPARWIN Presentation
03. 01. 2008
0 views

RIPARWIN Presentation

ioag9 jaxa briefing
03. 01. 2008
0 views

ioag9 jaxa briefing

social structure
19. 02. 2008
0 views

social structure

investing in the future
04. 03. 2008
0 views

investing in the future

Secondary Math Handout
07. 08. 2007
0 views

Secondary Math Handout

Roundtable
26. 10. 2007
0 views

Roundtable

NicholasEberstadt
15. 10. 2007
0 views

NicholasEberstadt

YTB 052007
12. 03. 2008
0 views

YTB 052007

raicevic
18. 03. 2008
0 views

raicevic

sbp 07
25. 03. 2008
0 views

sbp 07

purchasing sp presentation
20. 09. 2007
0 views

purchasing sp presentation

CSAPA Awareness2005
07. 08. 2007
0 views

CSAPA Awareness2005

FinalReport
22. 10. 2007
0 views

FinalReport

IJCDlineNojiri
09. 10. 2007
0 views

IJCDlineNojiri

DFT KeyChallengesNicNewm an
05. 10. 2007
0 views

DFT KeyChallengesNicNewm an

ILejarraga
07. 08. 2007
0 views

ILejarraga

EP Tecon 0405
19. 06. 2007
0 views

EP Tecon 0405

famigliaim presaanto 3
18. 06. 2007
0 views

famigliaim presaanto 3

Bulldogs Best Books 1211
18. 06. 2007
0 views

Bulldogs Best Books 1211

btw e 008 moriresearch
18. 06. 2007
0 views

btw e 008 moriresearch

BPL Sanyo JV Pressrelease
18. 06. 2007
0 views

BPL Sanyo JV Pressrelease

bite overview
18. 06. 2007
0 views

bite overview

biogas
18. 06. 2007
0 views

biogas

BILBAO
18. 06. 2007
0 views

BILBAO

Benef oport
18. 06. 2007
0 views

Benef oport

formazrete
18. 06. 2007
0 views

formazrete

lect 4 1113 Class Ig Rx1
20. 09. 2007
0 views

lect 4 1113 Class Ig Rx1

ebs2 elearn07
19. 06. 2007
0 views

ebs2 elearn07

boiron
18. 06. 2007
0 views

boiron

fiscal
18. 06. 2007
0 views

fiscal

12 productivity quiz
16. 06. 2007
0 views

12 productivity quiz

10 1
16. 06. 2007
0 views

10 1

215 Pics With Captions
16. 06. 2007
0 views

215 Pics With Captions

2007 Power Stroke
16. 06. 2007
0 views

2007 Power Stroke

20070422
16. 06. 2007
0 views

20070422

20070225
16. 06. 2007
0 views

20070225

2005AM LC 2C
16. 06. 2007
0 views

2005AM LC 2C

2004 4082OPH1 01 Tiefer
16. 06. 2007
0 views

2004 4082OPH1 01 Tiefer

1kanrap
16. 06. 2007
0 views

1kanrap

1kanpres
16. 06. 2007
0 views

1kanpres

1kanintro
16. 06. 2007
0 views

1kanintro

1kancom
16. 06. 2007
0 views

1kancom

19 Flake 071706
16. 06. 2007
0 views

19 Flake 071706

OIF Presentation Final Sept07
05. 01. 2008
0 views

OIF Presentation Final Sept07

12nightacts
16. 06. 2007
0 views

12nightacts

Fri 0830 RegionalAQ liao 1 pc
16. 10. 2007
0 views

Fri 0830 RegionalAQ liao 1 pc

bullismo
18. 06. 2007
0 views

bullismo

ARVs friends or foes McCoy
28. 12. 2007
0 views

ARVs friends or foes McCoy

Rock types silica sat
20. 09. 2007
0 views

Rock types silica sat

Threats to our Water
29. 02. 2008
0 views

Threats to our Water

SIVplanmeet svg3c Shakir
07. 08. 2007
0 views

SIVplanmeet svg3c Shakir

Rajesh Mehta
07. 08. 2007
0 views

Rajesh Mehta

FER 9 und 20
18. 06. 2007
0 views

FER 9 und 20

georgevidor
16. 11. 2007
0 views

georgevidor

beo presentation
18. 06. 2007
0 views

beo presentation

EVACAR Otesis
18. 06. 2007
0 views

EVACAR Otesis

Calvin Dude
07. 08. 2007
0 views

Calvin Dude

PRACTICAL4
29. 12. 2007
0 views

PRACTICAL4

cuamcfarland
20. 09. 2007
0 views

cuamcfarland

UHART
24. 11. 2007
0 views

UHART

News CIRIA document
01. 01. 2008
0 views

News CIRIA document

EverythingDigital
07. 08. 2007
0 views

EverythingDigital

ntra Master B
23. 10. 2007
0 views

ntra Master B

FSGDevCon20060419
15. 11. 2007
0 views

FSGDevCon20060419

Context06
15. 10. 2007
0 views

Context06

4 brittle I
20. 09. 2007
0 views

4 brittle I

WBTi
07. 08. 2007
0 views

WBTi

BTSA Technology Bytes
18. 06. 2007
0 views

BTSA Technology Bytes

FCP05 PD Flaum
06. 08. 2007
0 views

FCP05 PD Flaum

14 20H 10 1103 Dr SEARO
07. 08. 2007
0 views

14 20H 10 1103 Dr SEARO

echt Zeit
19. 06. 2007
0 views

echt Zeit

dortmund
19. 06. 2007
0 views

dortmund